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Differential insular cortex subregional vulnerability to a-synuclein pathology in Parkinson’s
disease and dementia with Lewy bodies
Aim: The insular cortex consists of a heterogenous
cytoarchitecture and diverse connections and is
thought to integrate autonomic, cognitive, emotional
and interoceptive functions to guide behaviour. In
Parkinson’s disease (PD) and dementia with Lewy bod-
ies (DLB), it reveals a-synuclein pathology in advanced
stages. The aim of this study is to assess the insular
cortex cellular and subregional vulnerability to a-synu-
clein pathology in well-characterized PD and DLB sub-
jects. Methods: We analysed postmortem insular tissue
from 24 donors with incidental Lewy body disease, PD,
PD with dementia (PDD), DLB and age-matched con-
trols. The load and distribution of a-synuclein pathol-
ogy and tyrosine hydroxylase (TH) cells were studied
throughout the insular subregions. The selective
involvement of von Economo neurons (VENs) in the
anterior insula and astroglia was assessed in all groups.
Results: A decreasing gradient of a-synuclein pathology
load from the anterior periallocortical agranular towards
the intermediate dysgranular and posterior isocortical
granular insular subregions was found. Few VENs
revealed a-synuclein inclusions while astroglial synucle-
inopathy was a predominant feature in PDD and DLB.
TH neurons were predominant in the agranular and dys-
granular subregions but did not reveal a-synuclein inclu-
sions or significant reduction in density in patient
groups. Conclusions: Our study highlights the vulnera-
bility of the anterior agranular insula to a-synuclein
pathology in PD, PDD and DLB. Whereas VENs and
astrocytes were affected in advanced disease stages, insu-
lar TH neurons were spared. Owing to the anterior insu-
la’s affective, cognitive and autonomic functions, its
greater vulnerability to pathology indicates a potential
contribution to nonmotor deficits in PD and DLB.
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Introduction
Parkinson’s disease (PD) is mainly characterized by
motor symptoms which result from the death of
dopaminergic neurons in the substantia nigra pars
compacta [1]. Yet, nonmotor deficits, including cogni-
tive impairment, autonomic dysfunction and neuropsy-
chiatric symptoms are highly prevalent in PD [2–4].
In addition, dementia with Lewy bodies (DLB), one of
the most common causes of dementia, is defined by
an early onset of fluctuating cognition, visual halluci-
nations and dementia preceding or occurring
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concomitantly within 1 year from the onset of parkin-
sonism [5,6]. PD with dementia (PDD) and DLB show
considerable clinical overlap and may be considered as
two ends of a disease spectrum with different timing of
parkinsonism and dementia [7–9]. In PD and DLB, the
catecholaminergic, dopaminergic and nor-adrenergic
nuclei in the brainstem and cortex are particularly vul-
nerable to a-synuclein pathology and degeneration
[10]. Loss of these monoaminergic neurons most likely
contribute to the cognitive and neuropsychiatric deficits
in these disorders [10,11]. It is therefore imperative to
study the regional and cellular correlates of clinical def-
icits in PD and DLB. Of interest in this respect, the
insular cortex is involved in the integration of
somatosensory and autonomic information with higher
cognitive functions [12–14]. It also plays a role in emo-
tion recognition, cognition and awareness of interocep-
tive information and thus acts as the basis of self-
awareness [15]. It has been associated with multiple
neuropsychiatric disorders, such as anxiety, depression
and bipolar disorder [16]. However, little is known
regarding the selective vulnerability of catecholaminer-
gic and other cells in this region in PD and DLB.
According to Braak staging for PD, a-synuclein
pathological aggregates progress from brainstem to lim-
bic brain regions in the prodromal and early stages of
the disease followed by the neocortex in more advanced
stages. Meanwhile, the insular cortex is affected in
advanced stages of the disease (5 and 6) [17–19]. Atro-
phy of the insula in PD, assessed by neuroimaging, has
also been associated with executive dysfunction, one of
the most common and early cognitive dysfunctions in
PD [20]. Moreover, a reduction in dopaminergic recep-
tor binding and grey matter density have been associ-
ated with mild cognitive impairment in PD [21,22].
Insular atrophy was also found in patients with prodro-
mal DLB and correlates with impairment in attributing
mental states to others in patients with probable DLB
[23,24].
Anatomically, the insula is a heterogeneous region
hidden deep within the Sylvian fissure and is widely con-
nected to the brain. Macroscopically, the insula is
divided into anterior and posterior gyri both constituting
different cytoarchitectures. Microscopically and in order
from ventro-rostral to dorso-caudal, the main subregions
are defined as anterior periallocortical agranular (Ia),
anterior- middle pro-isocortical dysgranular (Id), and
posterior isocortical granular (Ig) and hypergranular (G)
subregions, based on the cytoarchitecture and number
of layers [25–28]. According to the location and connec-
tivity, the agranular insula mostly relays projections to
limbic regions and the granular insula mostly projects to
cortical areas [12,29]. Preferential projections to the
anterior insula arise from the prepiriform olfactory, orbi-
tofrontal and rhinal cortices. On the other hand, only
the posterior insula receives projections from the sec-
ondary somatosensory areas. The dysgranular insula
represents a transitional zone with a variety of limbic
and cortical connections [29,30] (Figure 1). On the
basis of the current staging criteria and earlier involve-
ment of the limbic cortex compared to the neocortex in
PD, the diversity in cytoarchitecture of the insular subre-
gions could provide insight into the underlying charac-
teristics predisposing to degeneration. Moreover, the
presence of von Economo neurons (VENs), spindle
shaped neurons in layer Vb, mostly in the agranular
insula, adds to the uniqueness of the region. VENs are
implied to play a role in social awareness, emotional pro-
cessing and autonomic control [31,32]. Despite specula-
tions on their role in cognitive decline in disease [23], it
remains unknown if VENs are vulnerable to a-synuclein
pathology in PD and DLB. Moreover, the selective vul-
nerability of catecholaminergic neurons in the insular
cortex subregions remain unknown.
Considering the wide-spread connectivity of the
insula, the cellular heterogeneity and differential func-
tional properties of the insular subregions, we hypothe-
size that the periallocortical agranular subregion of the
insula displays greater vulnerability to a-synuclein
pathology in PD and DLB compared to the isocortical
subregions. To gain insight into the selective vulnera-
bility of the insular subregions and their cell types, we
performed a detailed analysis of the a-synuclein distri-
bution pattern throughout the insular cortex of sub-
jects with incidental Lewy body disease (iLBD), PD and
DLB. Our study provides data on the selective vulnera-
bility of VENs, catecholaminergic neurons and astro-
cytes within the insular subregions.
Materials and methods
Post mortem human brain tissue
Insular post mortem tissues from 21 donors with
iLBD, PD(D) and DLB (range = 60–93 years) and 3
age-matched controls (range = 68–79 years) were
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on behalf of British Neuropathological Society
NAN 2019; 45: 262–277
Insular cortex vulnerability in Parkinson’s disease 263
collected by the Netherlands Brain Bank (www.nbb.nl;
Netherlands) and the Normal Aging Brain Collection
Amsterdam (www.nabca.eu; Netherlands). All donors
had provided written informed consents for donation of
brain tissue and access to clinical and neuropathologi-
cal reports in compliance with ethical and legal guide-
lines. The main inclusion criteria were: (i) clinical
diagnosis of PD(D) or DLB according to revised MDS
diagnostic criteria [6,33] and (ii) pathological confirma-
tion of diagnosis [34]. Subjects were excluded if they
had a long history of neuropsychiatric disorders or
suffered from insular infarcts.
The entire insula was dissected into 0.5–1 cm thick
blocks and defined according to its borders with orbito-
frontal and temporal cortices inferiorly and inferior
frontal gyrus operculum superiorly [35]. Tissue blocks
were cryo-protected with 30% sucrose, frozen and
stored at 30°C until further processing. The tissue
slices were then sectioned, using a sliding microtome,
into 60 lm thick sections.
Neuropathological assessment
For neuropathological diagnosis and staging, 6 lm
paraffin sections from several brain regions of all
donors were stained for a-synuclein, b-amyloid, hyper-
phosphorylated tau, haematoxylin and eosin (H&E),
a-synuclein, TDP-43 and congo-red according to cur-
rent diagnostic guidelines of BrainNet Europe [34].
Confirmation of either iLBD, PD or DLB and concommi-
tant Alzheimer’s disease (AD) pathology was based on
guidelines using Braak staging for neurofibrillary tan-
gles (Braak NFT 0–6), Braak a-synuclein (Braak a-syn
0–6), Thal phase for b-amyloid (0–5), and ABC scoring
system [17,36–39]. Glial tauopathy such as age related
tauopathy of the astroglia (ARTAG) and primary age
related tauopathy were assessed primarily in the tem-
poral cortex, olfactory cortex and amygdala [40,41].
Immunohistochemistry
For a-synuclein immunostaining, free-floating 60 lm sec-
tions were pretreated with 98% formic acid (Sigma-
Aldrich, Darmstadt, Germany) and incubated with pri-
mary antibody mouse anti-a-synuclein (1:2000; 610786;
BD Biosciences, Berkshire, UK), as previously described
[42]. Adjacent sections were pretreated with citrate buffer
pH 6.0 in a steamer (95°C) and stained using antibodies
against tyrosine hydroxylase (TH) antibody (rabbit anti-
TH, 1:1000, incubation for 24 h; AB152, Merck Milli-
pore, Darmstadt, Germany) or astrocytic marker glial fib-
rillary acidic protein (GFAP) (rabbit anti-GFAP 1:4000,
incubation for 72 h; Z0334; DAKO, Glostrup, Denmark).
The sections were incubated in the secondary antibody
biotinylated IgG (1:200, Vector Laboratories, Burlingame,
CA, USA) followed by standard avidin-biotin complex
(1:200, Vectastatin ABC kit, Standard; Vector Laborato-
ries) in TBS or rabbit Envision (DAKO) for 2 h. Then 3,30-
diaminobenzidine (DAB) was used to visualize staining
and sections were mounted and counter-stained with
thionin (0.13%, Sigma-Aldrich, Darmstadt, Germany).
For double staining of TH and a-synuclein, liquid perma-
nent red (DAKO) and DAB were used.
For immunofluorescent double staining of a-synuclein
and GFAP, immunostaining was performed as above for
72 h at 4°C followed by incubation with donkey anti-
mouse coupled with Alexa Fluor 488 (1:400; Molecular
Probes, Waltham, MA, USA), donkey anti-rabbit coupled
with Alexa Fluor 594, and diamidino-2-phenylindole
Figure 1. Macroscopy of the insular cortex subregions and
corresponding connections. The insular cortex is seen within the
sylvian fissure. The agranular insula (A-Ia) is seen ventro-
anteriorly (red), is connected to the olfacotory cortex,
orbitofrontal, amygala and temporopolar region. While the
dysgranular insula (A-Id) is seen dorsally (orange) and is
connected to various limbic and neocortical regions. Although the
granular insula (P-Ig) (green) is mostly present within the
posterior insula. It is preferentially connected to the
somatosensory cortex, parietal cortex and cingulate. Some regions
are coloured to outline connections to the insular subregions
including the prefrontal cortex and temporopolar cortex. Amyg,
amygdala; Cing, cingulate gyrus; Ent, entorhinal cortex; Ofg,
orbitofrontal gyrus; PC, parietal cortex; Prec, precentral sulcus;
Prefr, prefrontal cortex; Pre-olf, prepiriform part of olfactory
cortex; SS, somatosensory cortex; STS, superior temporal sulcus;
Tp, temporopolar cortex.
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(4,6)dihydrochloride (DAPI; Sigma) for 2 h. The tissue sec-
tions were then mounted on glass slides and cover-slipped
withmowiol as mountingmedium (4-88 Calbiochem).
Bright-field and confocal laser scanning microscopy
Digital images of the immuno-stained slides were made
with a photomicroscope (Leica DM5000) equipped with
colour camera DFC450, Leica LASV4.4 software and
639 oil objective lens. Immunofluorescent labelling was
visualized using confocal laser scanning microscopy
(CLSM) LEICA TCS SP8 (Leica Microsystems, Jena, Ger-
many). Image acquisition was done using 1009/1.4 NA
objective lens, 405 nm diode, and pulsed white light laser
(80 Hz) with excitation wavelengths 405, 499 and
598 nm. Afterwards, deconvolution of image stacks was
performed using Huygens Professional software (Scien-
tific Volume Imaging, Hilversum, the Netherlands). Colo-
calization analyses to assess the co-occurrence and
correlation of GFAP and a-synuclein were performed
using Imaris software 8.3 (Bitplane, South Windsor, CT,
USA). Deconvolved fluorescent images acquired using
CLSM were used and a region of interest (ROI) was out-
lined for colocalization. The correlation between both
channels was determined using Pearson’s correlation coef-
ficient and Mander’s overlap coefficient (MOC) as well as
the percentage of ROI colocalized (http://www.bitplane.c
om/imaris/imariscoloc).
Definition of insular subregions
The anatomical and cytoarchitectural characteristics of
the insular subregions were identified in Nissl stained
sections by YF and WvdB based on the granularity and
density of layers II and IV. For simplicity, definitions
were based on the four known subregions: agranular,
dysgranular and granular/hypergranular insula [12].
The agranular insula was defined based on its ventral
anterior location, absence of layers II and IV, and clus-
ters of VENs in layer Vb. The dysgranular region is dorsal
to the agranular and has more distinguished layers II
and IV. The granular and hypergranular regions were
defined based on their dorso-caudal and mid to posterior
location and consisted of increasingly dense and granu-
lar layers II and IV [28] (Figure 2). VENs and fork cells
were assessed in layer V of the agranular insula and
VENs were defined based on their spindle-shaped mor-
phology and anatomical location [43]. a-Synuclein
inclusions in the insular cortex were assessed using an
ordinal semiquantitative score, ranging from 0 to 3 in
60 lm sections. The scoring criterium was: 0 = absent,
1 = few dot-like deposits or sparse LNs present + 1–5
LB, 2 = Moderate LN present in all layers + 5–10 LB,
3 = Severe LNs present in all layers + >10 LB in 209
objective field. a-synuclein deposits were counted in all
layers and ≥3 frames. The subregions were first defined
and the scoring was performed by YF and EO as described
(Table S1). Kruskal–Wallis test was conducted to evalu-
ate differences in the distribution pattern of a-synuclein
pathology between the three insular subregions (agranu-
lar, dysgranular, and granular) and across groups
(Figure S1). Statistical significance was set at 0.05.
Quantification of the density of TH-immunoreactive
neurons in insular subregions
In total, 12 PD(D) and DLB subjects, from which the
entire insula was available, were included for
(a) (b) (c)
Figure 2. Definition of insular subregions in 60 lm thick sections. (a) Granular insular grey matter shows uniform and well defined
granular layers II and IV in an iLBD case. (b) Dysgranular insula shows less dense and granular layers II and IV. (c) Agranular insula
grey matter is shown lacking layers II and IV. iLBD, incidental Lewy body disease; II, layer two; III, layer three; IV, layer four.
Magnification: 25 9, scale bar 500 lm.
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
NAN 2019; 45: 262–277
Insular cortex vulnerability in Parkinson’s disease 265
quantitative analysis of the TH immunoreactive (TH-ir)
neuronal density (neurons/mm2) in the agranular and
dysgrnaular subregions. The granular insula did not
reveal TH-ir neurons and was not included in the density
assessment. The insular subregions were defined and all
layers were evaluated by YF and EO for presence of TH-ir
neurons. A region of interest (ROI) was then defined at
259 magnification from midlayer III to midwhite matter
layer where most TH-ir neurons were located, using the
stereoinvestigator software (11.06.200; MBF Bioscience,
Delft, The Netherlands). TH-ir neurons had a diameter
range from 7 to 29 lm, consistent with data available in
the literature [44]. As only few TH-ir neurons were
observed in the insular subregions, we determined the
local density in the agranular and dysgranular subre-
gions within the anterior insula in one section per case.













phase ABC Cognitive and psychiatric deficits
HC
HC_1 M 68 Control N/A N/A 0 I, ARTAG 2 A1B1C0 N/A
HC_2 M 74 Control N/A N/A 0 II 3 A2B1C1 N/A
HC_3 F 79 Control N/A N/A 0 II 3 A2B1C0 N/A
iLBD and PD
iLBD-1 F 88 iLBD N/A N/A 4 III 2 A2B2C1 N/A
PD-1 M 78 PD 75 3 3 I 0 A0B1C0 N/A
PD-2 F 93 PD 91 2 3 II 2 A1B1C0 Depression
PD_3 M 77 PD 66 11 5 II 1 A1B1C0 Word-finding difficulties, poor attention
& concentration
PD_4 F 68 PD 52 16 5 II 1 A1B1C0 MCI
PD_5 F 73 PD 70 3 4 II 2 A1B1C0 Anhedonia and apathy
PDD
PDD-1 F 88 PDD 73 15 5 II, ARTAG
and PART
0 A0B1C0 Delirium, anxiety, RBD, &
hallucinations
PDD-2 M 74 PDD 67 7 6 II, ARTAG 3 A2B1C0 Depression, panic attacks, &
hallucinations
PDD-3 F 74 PDD 61 13 6 III 3 A2B2C1 Delirium and hallucinations
PDD-4 F 81 PDD 73 8 6 II, ARTAG 3 A2B1C1 Delirium, hallucinations, & MCI
PDD-5 M 75 PDD 69 6 6 II, ARTAG 1 A1B1C0 RBD, depression, MCI
PDD-6 M 70 PDD 51 19 6 III, ARTAG 3 A2B2C0 Cognitive impairment and delirium
PDD-7 F 88 PDD 82 6 6 II, ARTAG 1 A1B1C0 Hallucinations & memory complaints
PDD_8 M 81 PDD 63 18 6 III, ARTAG,
PART
0 A0B2C0 Delirium, hallucinations, anxiety
PDD_9 F 83 PDD 69 14 6 IV, ARTAG,
PART
0 A0B2C0 Delirium, hallucinations, dementia
PDD_10 M 71 PDD 45 26 5 II, ARTAG 1 A1B1C0 Hallucinations, delirium, disturbed
speech & concentration
DLB
DLB-1 M 67 DLB 64 3 6 V, ARTAG 5 A3B3C3 RBD, hallucinations, apraxia, &
Capgras syndrome
DLB-2 M 75 DLB 73 2 6 III, ARTAG 4 A2B2C3 Paranoia, psychosis, hallucinations &
Charles Bonnet syndrome
DLB-3 M 81 DLB 77 4 6 III 3 A2B2C0 RBD, anxiety, depression, disinhibition,
& hallucinations
DLB_4 M 78 DLB 72 6 6 I, ARTAG 3 A2B1C0 Memory complaints & Dementia
DLB_5 M 60 DLB 53 7 6 0 0 A0B0C0 Impaired memory, language,
concentration, & psychosis
ABC score, A–C (0–3); ARTAG, ageing-related tau astrogliopathy; Braak NFT, 0–6; Braak a-syn, 0–6; DLB, dementia with Lewy bodies;
DD, disease duration; HC, Healthy control; iLBD, incidental Lewy body disease; MCI, mild cognitive impairment; NFT, neurofibrillary tan-
gles; PART, primary age-related tauopathy; PD, parkinson’s disease; PDD, PD dementia; RBD, REM sleep behavioural disorder; Thal
phase, 0–5; a-syn, a-synuclein; N/A, not applicable.
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The TH-ir neurons were included in the density assess-
ment when they met the following criteria: (i) soma with
diameter >7 lm; (ii) (part of) neurites visible; (iii) soma
was located within or intersecting the lines of the ROI.
TH-ir neurons were then counted at 4009 using the
Meander scan. The local density of TH-ir neurons (neu-
rons/mm2) was calculated per subregion for each case as
previously described by others [10].
Statistical analysis
SPSS version 22 (IBM, Armonk, New York, USA) was
used for all statistical analyses. One-way ANOVA (multi-
ple group comparison) with Bonferroni post hoc test was
used to examine differences in subject demographics
between groups. The Kruskal–Wallis test was used to
compare the TH density of the agranular and dysgranu-
lar insula. Differences in TH density per subregion
between the PD, PDD, DLB patients and controls were
analyzed using one-way ANOVA. Furthermore, the cor-
relation between TH density per subregion and a-synu-
clein was examined using Spearman’s rho. Statistical
significance was set at 0.05.
Results
Clinical and neuropathological characteristics of PD
and DLB donors
All PD(D) and DLB donors included in this study had
Braak a-synuclein stages ranging from III to VI and dis-
ease duration ranged from 2 to 26 years. The PDD and
DLB donors had advanced Braak a-synuclein stages
(5–6), moderate to severe cognitive impairments with
memory, attention, language problems and REM sleep
behavioural disorder. Several neuropsychiatric symptoms
were reported including visual hallucinations, delirium,
depression, anxiety and panic attacks. Moreover, ARTAG
was present in all PDD cases except for PDD_3 who
showed severe astroglial degeneration instead. NFT and
b-amyloid plaques were most severe in DLB-1 and DLB-2
who had a short disease duration (2–3 years) as well as a
family history of AD and early dementia. The demograph-
ics and neuropathological staging of all donors included
in this study are summarized in Table 1.
Distribution pattern of a-synuclein pathology in the
insular cortex of iLBD, PD and DLB
We observed a decreasing gradient of a-synuclein
pathology load from the ventral anterior agranular
subregion to the dorsal dysgranular and posterior
dorso-caudal granular subregions. In iLBD and PD(D),
a-synuclein deposits were present in all layers of the
agranular insula, whereas in the dorsal dysgranular
less immunoreactivity was observed. In the granular
insula, a-synuclein immunoreactivity was minimal or
absent. LNs were present in all layers while LBs were
predominantly found in the deep layers V and VI.
The iLBD insular cortex (iLBD-1), Braak a-synuclein
stage 4/6, showed few LN in both agranular and dys-
granular regions and very mild immunoreactivity in
the granular insula. a-Synuclein immunoreactive fea-
tures consisted of dot-like deposits, few LNs, sparse LBs
and astroglial deposits (Figure 3a–c). PD-1, Braak
a-synuclein stage 3/6, revealed very sparse a-synuclein
inclusions in all subregions (Figure 3d–f). PD-2, Braak
a-synuclein stage 3/6, showed moderate to severe LN
and few LBs in the deep layers of the agranular insula.
The granular and dysgranular subregions contained
bulgy LNs as well as a mild to moderate number of
LNs and LBs, respectively (Figure 3g–i).
Figure 3. Distribution pattern of a-synuclein in insular subregions. iLBD shows mild LNs and astroglial a-synuclein inclusions in layer I
of agranular insula (a), few glial inclusions in dysgranular insula (b), and sparse dot-like aggregates in granular insula (c). PD-1
agranular insula shows a LB-like inclusion and dot-like aggregates (d), the dysgranular insula shows bulgy LNs in layer I (e), and the
granular insula shows an intracellular LB inclusion (f). PD-2 shows many LNs inclusions in agranular insula and glial a-synuclein (g)
and less but bulgy LN in dysgranular (h) and granular regions (i). In PDD-2 severe astroglial a-synuclein inclusions are shown in
agranular insula (j) few LBs and LNs in dysgranular insula (k). The granular insula shows dot-like aggregates and astroglial a-synuclein
(l). In PDD-1 agranular insula, very long LNs and some dot-like aggregates are seen in layer I (m). Dysgranular insula in PDD-1 shows
granular cytoplasmic inclusions in neurons and a LB (n) while the granular insula shows less aggregates and a LB in the infragranular
layer (o). In DLB-1, severe a-synuclein inclusions are seen in agranular insula throughout all layers (p). Severe astroglial inclusions are
seen in the supragranular layers of dysgranular and granular insula (q,r). In DLB-2, a cluster of dystrophic LNs and glial inclusions are
shown in layer II of the agranular insula (s). The dysgranular insula contains LNs and dot-like structures (t) also abundant in the
granular insula superficial layers (u). DLB, dementia with Lewy bodie; iLBD, incidental Lewy body disease; LB, Lewy bodies; LN, Lewy
neurites; PD, Parkinson’s disease; PDD, Parkinson’s disease dementia. Magnification: 630 9 , scale bar 50 lm.
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In PDD 1-2, Braak a-synuclein stage 6/6, the same
gradient of a-synuclein immunoreactivity was present
with highest load of pathology in agranular insula.
PDD-1 showed very long LNs in the superficial layers
of the agranular insula and a mild to moderate a-synu-
clein load in the granular and dysgranular insula,
respectively. Astroglial a-synuclein inclusions were also
found (Figure 3j–o). Other PDD cases showed similar
distribution of pathology throughout the subregions as
well as astroglial synucleinopathy and degeneration.
In contrast, DLB-1 and 2, Braak a-synuclein stage
6/6, showed severe a-synuclein inclusions in all layers
of the agranular/dysgranular insula and severe proto-
plasmic astroglial a-synuclein inclusions. In the granu-
lar insula, a high load of a-synuclein inclusions with
relative sparing of layers III/IV was observed
(Figure 3p–u). Other DLB cases showed a-synuclein
distribution similar to PD(D).
Assessment of the semiquantitative scores of a-synu-
clein between the three insular subregions showed a sig-
nificant difference [v2 (2, N = 63) = 9,099, p = 0.011].
To assess pairwise differences across the three subre-
gions, follow-up tests were performed. Pairwise compar-
isons between the subregions showed further significant
differences between the agranular and granular
subregions as well as dysgranular and granular subre-
gions (P = 0.005 and 0.043, respectively) (Figure 4).
Morphology of a-synuclein immunoreactive
structures in the insular subregions
In PDD and DLB, severe synucleinopathy was observed
in astrocytes (Figure 5a–c). The supragranular layers
I–III, showed moderate to severe LNs variable in shape
and size, thread-like, bulgy and long. Layers V and VI
contained a predominance of cortical LBs, which
increased in gradient from agranular to granular subre-
gions. Astroglial degenerative changes in the form of
detached astroglial processes with bulbous and dough-
nut-shaped end-feet were present in superficial layers
in P DD and DLB. Fuzzy astrocytes, with granular
accumulations along their processes were also seen in
PDD with ARTAG (Figure 5d–f).
Neuronal vulnerability to a-synuclein pathology in
insular subregions
TH-ir interneurons were predominantly present in the
deeper layers (V–VI) of the agranular and dysgranular
subregions of the insular cortex and occasionally in
layer III and white matter. The granular insular cortex
did not contain TH-ir neurons. These neurons were
unipolar, bipolar, tripolar and multipolar. They were
also usually surrounded by a mesh of beaded dopamin-
ergic fibres. Assessment of TH and a-synuclein did not
reveal any colocalization. Furthermore, there were no
significant differences in the density of TH-ir neurons
between groups for both agranular and dysgranular
subregions (P = 0.56 and P = 0.82, respectively) (Fig-
ure 6). No significant correlation was found between
subregional TH-ir density and a-synuclein scores.
Only few VENs and fork cells in layer V of fronto-
insular region revealed a-synuclein inclusions in PD-2
and PDD 1 and 2. VENs showed granular cytoplasmic
a-synuclein inclusions and LBs. They were also fre-
quently surrounded by astroglial cells showing thorn-
shaped a-synuclein immunoreactivity (Figure 7).
Relationship between astrocytes and a-synuclein
pathology
Double labelling of GFAP and a-synuclein was per-
formed to examine the relationship between astrocytes
Figure 4. Semiquantitative analysis of a-synuclein pathology
across the insular subregions. The local density of a-synuclein
wass assessed at 200 9 magnification. A significant difference in
subregional distribution of a-synuclein pathology was observed
[v2 (2, N = 63) = 9099, P = 0.011]. Pairwise comparison
between different subregions showed a significant difference
between the agranular and granular subregions as well as
dysgranular and granular subregions (P = 0.005 and 0.043,
respectively).
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and a-synuclein inclusions. Astrocytes with multiple
varicosities were predominantly found in the agranular
and to a lesser extent in the dysgranular insula, in
both controls and patients, possibly representing vari-
cose projection astrocytes (VPA). A VPA in the infra-
granular layer in PD-2 was found containing a cluster
of cytoplasmic a-synuclein forming a mesh-like struc-
ture (Figure 8a). Other protoplasmic and interlaminar
astrocytes examined in PDD and DLB showed a-synu-
clein deposits around the cell body and processes (Fig-
ure 8). Further colocalization analysis in VPA showed
a positive correlation between a-synuclein and GFAP
(MOC for channels A and B = 0.94 and 0.27, repec-
tively) (Figure S2). Analysis and reconstruction indicate
possible compartmentalization of the a-synuclein within
the astrocytic cell body (Figure S2).
Discussion
In this case series, we observed a decreasing gradient
in the load of a-synuclein immunoreactivity from the
anterior periallocortical agranular subregion to the
intermediate pro-isocortical dysgranular and posterior
isocortical granular insula in iLBD, PD and DLB sub-
jects. This was particularly evident in iLBD and PD(D)
with the highest load of neuropathological inclusions
in the agranular insula. In DLB with high AD patho-
logical stages, there was also extensive a-synuclein
immunoreactivity in the granular region with an abun-
dance of LBs in the infragranular layers V/VI, and rela-
tive sparing of layers III/IV. Some VENs, but not TH-ir
neurons, in the anterior insula revealed a-synuclein
inclusions in PD(D). Astrocytes were also vulnerable to
a-synuclein inclusions and showed degenerative
changes at all disease stages, yet most prominent in
PDD and DLB.
The presence of a gradient for a-synuclein pathology
across the insular cortex, from the anterior agranular
to posterior granular subregions, has previously been
documented for NFT and b-amyloid pathology in post
mortem insular tissue of AD patients [45]. This
decreasing pathological gradient appears to be
(a) (b) (c)
(d) (e) (f)
Figure 5. Cell specific morphology and inclusions in Lewy body diseases. In PDD-2 with astroglial tauopathy, infragranular layer of
agranular insula show astroglial-to-neuronal a-synuclein inclusions (a), an elongated a-synuclein positive process with bulbous endings
(possibly glial) surrounded by astroglial a-synuclein inclusions (*) and LNs (b). DLB-2 shows LB inclusions, LNs and astroglial a-synuclein
(*) within the deep infragranular layers (c). Loose GFAP + astrocytic processes are shown containing bulbous end feet and donut-shaped
structures in the supragranular layers of the agranular insula in DLB-2 (d). PDD-1 with astroglial tauopathy shows small and
dysmorphic astrocytes containing multiple varicosities within their processes, possibly representing fuzzy astrocytes (e). A
GFAP + astrocyte is shown surrounded by disorganized processes in DLB-2 (f). Magnification: 630 9 , scale bar 50 lm. DLB, dementia
with Lewy bodie; LB, Lewy bodies; LN, Lewy neurites; PDD, Parkinson’s disease dementia; GFAP, glial fibrillary acidic protein.
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consistent with differences in cytoarchitecture, cell
types and myelination in the insular subregions [28].
Accordingly, the agranular insula comprises the high-
est density of acetylcholinesterase and lowest density of
myelinated fibres while the opposite exists in the granu-
lar subregions [46]. The vulnerability of the agranular
insula relative to the late and sparse involvement of
the granular insula corresponds with an inverse rela-
tionship between myelination and neuropathological
lesions in both AD and PD [47]. The agranular insula
also comprises of preferential connections to the olfac-
tory and rhinal cortices which are affected in the early
stages of PD and show a similar allocortical cytoarchi-
tecture [18,29]. In line with this, the granular insula
connects to the isocortical somatosensory and cingulate
cortices and is affected in later stages of the disease
[29]. Considering the insular phylogenetic and ontoge-
netic variations [48], the insular subregions reflect the
global regional involvement in PD, as described by
Braak and colleagues. Moreover, cognitive and neu-
ropsychiatric deficits were prominent in our cohort and
particularly with more advanced Braak stages. Consider-
ing the anterior insular cortex connectivity, a-synuclein
pathology and cell death in the agranular insula may
contribute to autonomic, cognitive and psychiatric
symptoms in PD(D) and DLB [49].
TH-ir neurons ranged from bipolar to multipolar,
predominantly resided in the deeper layers of the
agranular and dysgranular insular cortex subregions
and did not show any a-synuclein deposits. Generally,
catecholaminergic neurons in the brain stem are
known to be selectively vulnerable to Lewy pathology
in PD [50]. Yet, cortical TH-ir neurons remain mysteri-
ous and show substantial differences in distribution
pattern across the brain. Although the lowest density is
present within the somatosensory cortex, the highest is
present in the cingulate cortex [11]. This variation is
also represented by the insula with a decreasing gradi-
ent of TH-ir neurons from agranular/dysgranular to
granular/hypergranular insula, adding to the variation
in cellular compositions across the insular subregions.
Although a previous study showed reduction in TH-ir
neurons in PD compared to controls in multiple cortical
brain regions [10], we did not find a significant reduc-
tion, which may be the result of a limited sample size.
We also show that VENs are vulnerable to a-synuclein
Figure 6. Morphological characteristics of tyrosine hydroxylase immunoreactive (TH-ir) neurons, distribution pattern, and relationship
with a-synuclein deposits in the Insular cortex subregions. TH-ir neurons were predominant in layers V and VI, and were mostly bipolar
in morphology and few multipolar (a,b). No a-synuclein deposits (*) were present within the TH-ir neurons (brown) or their neurites;
these TH-ir neurons were often found surrounded by beaded dopaminergic fibres (c,d). There were no significant differences in TH-ir
neurons between groups in the agranular and dysgranular subregions (e,f). Magnification: 630 9 , scale bar: 50 lm.
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pathology in advanced PD(D). VENs have been impli-
cated in consciousness, emotion, cognition and social
awareness [31,43,51]. In this study, few VENs showed
a-synuclein inclusions relative to the greater involve-
ment of pyramidal neurons within the agranular
insula. Previous studies assessing VENs found hyper-
phosphorylated tau inclusions as well as significant cell
loss in Pick’s disease compared to AD [52,53]. Further-
more, VENs are known to be selectively vulnerable to
degeneration early in frontotemporal dementia as well
as early onset schizophrenia [31]. Other studies, how-
ever, have shown that VENs show a reduced density as
well as NFT in AD particularly in late stages of the dis-
ease compared to cognitively normal elderly controls
and super-agers, elderly who performed average for
their age group or above average for individuals in
their 50s and 60s, repectively [54,55]. VENs are uniqe
spindle shaped projection neurons with sparse dendritic
branching. They are therefore thought to function in
the rapid relay of inputs from the insula and anterior
cingulate cortex to other brain regions. This in turn
would allow rapid control of behavior during changing
social situations [56]. Recent biochemical analyses
showed that these neurons may also possess a novel
type of cortical monoaminergic function due to their
expression of VMAT2 which packages monoamines
into vesicles [57]. Moreover, assessment of the func-
tional connectivity of regions containing VENs showed
their involvement in networks involved in salience pro-
cessing, allowing for rapid relay of information to other
brain regions and thus controlling attention [58]. The
salience network, formed of anterior ventral frontoinsu-
lar region and anterior cingulate cortex, is presumed to
play a role in detecting salient stimuli and directing
attention to such stimuli by coordinating between
other brain networks to facilitate a goal-directed beha-
viour [59,60]. The salience network has been impli-
cated in PD where patients showed reduced
dopaminergic receptors within the network which con-
sequently could play a role in memory and executive
dysfunctions [61]. Despite previous implications on the
possible role of VENs in PD, our study is the first to
show their involvement in PD(D) and DLB. Future stud-
ies focusing on the loss of VENs in Lewy body diseases
Figure 7. a-synuclein deposits in VENs. (a) PD-2 shows granular LB inclusions (brown) along a VEN. (b) LB in VEN and surrounding
astrocytes in PD-2. (c) PDD-2 shows a VEN containing a large LB and multiple granular inclusions within the cell body, astroglial a-
synuclein inclusions are also seen. (d) PDD-1 shows LB in the soma and dendrite of a VEN. (e) a-synuclein inclusions are shown in a
fork cell in PDD-1. (f) DLB-2 agranular insula shows many deposits surrounding pyramidal neurons and rod shaped VEN. Magnification:
630 9 , scale bar 50 lm. PDD, Parkinson’s disease dementia; LB, Lewy bodies; DLB, dementia with Lewy bodie; VENs, von Economo
neurons.
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
NAN 2019; 45: 262–277






Figure 8. Relationship between a-synuclein immunoreactivity and astrocytes in insular cortex in PD(D) and DLB. a-synuclein (green) is
present within varicose projection astrocyte (GFAP, red) cell body in deep layer in the anterior insula in PD-2 (a). In PDD-2, an astrocyte
is shown containing a-synuclein aggregates and surrounded by a cluster of nuclei in the anterior insula (b). In DLB-3, a protoplasmic
astrocyte is shown surrounded by multiple a-synuclein aggregates but no inclusions were present within the astrocyte (c). DLB-1 shows
a-synuclein deposits surrounding the cell body of an interlaminar astrocyte in layer I (d) and similar inclusions are shown within a
protoplasmic astrocyte, its processes, and the surrounding clustered nuclei in the posterior insula in DLB-2 (e). Magnification 100 9 ,
Scale bar: 10 lm. DLB, dementia with Lewy bodie; PDD, Parkinson’s disease dementia; GFAP, glial fibrillary acidic protein.
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may provide some insight into their contribution to
autonomic and neuropsychiatric symptoms.
Other cells such as astrocytes have been previously
shown to contain a-synuclein inclusions in advanced
PD and parallel to the neuronal involvement in disease
[42]. However, minimal astrocytic activation and cyto-
plasmic a-synuclein inclusions were observed in PD
compared to other neurodegenerative diseases [62]. In
our series, we observed the enwrapment of astrocytic
cell bodies and processes with a-synuclein. Protoplas-
mic and interlaminar astrocytes showed extensive
synucleinopathy most severe in the agranular insula,
particularly in PDD with glial tauopathy (ARTAG).
However, it remains unknown what role astroglial
a-synuclein plays in disease progression and its rela-
tionship with other pathologies. Moreover, whether
astroglial tauopathy could play a role in the vulnerabil-
ity of astroglia to synucleinopathy and degeneration
remains unclear [63,64]. Another novel feature of the
agranular insula, is the presence of VPA. These
recently discovered astrocytes with varicosities along
their processes were found only in higher order pri-
mates and humans [65]. Recent studies proposed that
they may provide alternative pathways for long dis-
tance communication through cortical layers [65,66].
We report the presence of intracellular a-synuclein
inclusions within these VPA cells. Future studies study-
ing these cells in more detail may provide more insight
into their selective vulnerability and functional corre-
lates in PD and DLB. This is the first study to assess the
subregional neuropathological characteristics and selec-
tive vulnerability of the insular cortex in PD(D) and
DLB. The limitations of this study include a limited
sample size. Our study also does not include quantita-
tive data on the density of VENs in PD and DLB. Attri-
butable to the presence of VENs primarily within the
agranular insula and particularly perpendicular to the
pia, it requires a dissection approach different from that
used in the present study [53]. Future large clinico-
pathological studies including longitudinal data and
insular subregional analysis will aid in our understand-
ing of the impact of insular neurodegeneration on the
cognitive and psychiatric deficits in PD and DLB.
In conclusion, the distribution pattern of a-synuclein
pathology revealed a decreasing anterior-to-posterior
gradient in the insular cortex, representative of the dif-
ferential cytoarchitectural vulnerability in PD and DLB.
Our study also shows that VENs and astroglia are
vulnerable to a-synuclein pathology, particularly in
advanced Braak stages in PDD and DLB. These results
elucidate variations in the selective vulnerability of
neurons and astrocytes as well as the pathological dis-
tribution pattern between the allocortical and isocorti-
cal subregions of the insular cortex.
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Figure S1. Median a-synuclein pathology scores within
the insular subregions in PD, PDD and dementia with
Lewy bodies (DLB) patient groups.
Figure S2. Colocalization of astrocytes [glial fibrillary
acidic protein (GFAP)-red] and a-synuclein (green).
Table S1. Semiquantitative assessment of a-synuclein
pathology in inuslar subregions.
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